Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more →
Incyte's $750M buyout rocked by pause on key trial, asset cull Read more →
Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more →
Talent to power Life Sciences
Tech talent for Life Sciences
« All Events
Presentations from the Olink team on the value of combining genomic and proteomic data for the best insights into human disease and development of new therapeutics, and more. After, enjoy lunch and networking.